exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089321 RNA Name: hsa-miR-760 RNA Type: miRNA Chromosome: chr1 Starnd: + Coordinate: Start Site(bp): 93846880 End Site(bp): 93846899 External Links: hsa-miR-760

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABL1 chr9 130713016 130887675 + ACVR1B chr12 51951699 51997078 + ARID3B chr15 74541177 74598131 + C6orf89 chr6 36871870 36928964 + CHTF8 chr16 69118010 69132578 - DBNDD1 chr16 90004871 90020128 - DDX54 chr12 113157174 113185479 - DMWD chr19 45782947 45792845 - EFTUD2 chr17 44849948 44899445 - ITGA5 chr12 54395261 54419266 - MEF2D chr1 156463727 156500779 - PDCD6 chr5 271621 314974 + PDE8A chr15 84980440 85139145 + PDXK chr21 43719094 43762307 + RAE1 chr20 57351223 57379211 + SLC35B2 chr6 44254096 44257890 - TELO2 chr16 1493344 1510457 + TSPAN14 chr10 80454166 80533124 + WSB2 chr12 118032694 118062430 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000458 chr12 124071293 124074996 + hsa_circ_0000038 chr1 28800065 28802803 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand KCNQ1OT1 chr11 2608328 2699994 - MALAT1 chr11 65497688 65506516 + MIR194-2HG chr11 64889560 64893449 - NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG1 chr11 62851984 62855953 - TUG1 chr22 30969245 30979395 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.